Drug Details

General Information of the Drug (ID: DR1499)
Name
Laninamivir
Synonyms
Laninamivir; 203120-17-6; UNII-B408IW3GL5; R-125489; Laninamivir (CS-8958); B408IW3GL5; (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 5-(Acetylamino)-2,6-Anhydro-4-Carbamimidamido-3,4,5-Trideoxy-7-O-Methyl-D-Glycero-D-Galacto-Non-2-Enonic Acid; Laninamivir [INN:JAN]; Laninamivir (INN); LANI; R 125489; CHEMBL466246; SCHEMBL12284832; DTXSID60942457; BCPP000190; C13H22N4O7; BCP27633; EX-A4019; ZINC3985629; BDBM50009296; AKOS015850995; AKOS032947260; BCP9000836; DB12791; (2R,3R,4S)-3-acetamido-2-[(1R,2R)-2,3-dihydroxy-1-methoxy-propyl]-4-guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid; HY-14818; CS-0003575; Y0284; C21557; D09410; S-7726; 120L176; A814430; Q6487096; (2R,3R,4S)-3-acetamido-4-[bis(azanyl)methylideneamino]-2-[(1R,2R)-1-methoxy-2,3-bis(oxidanyl)propyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; (4S,5R,6R)-5-acetamido-4-carbamimidamido-6-((1R,2R)-3-hydroxy-2-methoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid; 2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-5-[(1-hydroxyethylidene)amino]-7-O-methylnon-2-enonic acid; 5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid; 5-Acetylamino-4-(diaminomethyl-amino)-6-(2,3-dihydroxy-1-methoxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid
    Click to Show/Hide
Molecular Type
Small molecule
Disease Influenza [ICD-11: 1E30] Phase 2 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C13H22N4O7
PubChem CID
502272
Canonical SMILES
CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N
InChI
1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1
InChIKey
QNRRHYPPQFELSF-CNYIRLTGSA-N
CAS Number
CAS 203120-17-6
DrugBank ID
DB12791
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Methylglyoxal      Saccharomyces cerevisiae     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MDCK CVCL_0422 Healthy Canis lupus familiaris
                    Experimental
                    Result(s)		 MGO has potent inhibitory activity against influenza viruses and also enhanced the effect of NA inhibitors.
Target and Pathway
Target(s) Proteasome alpha 1 (PSMA1)  Molecule Info  [3]
Proteasome alpha 2 (PSMA2)  Molecule Info  [3]
Proteasome alpha 3 (PSMA3)  Molecule Info  [3]
References
Reference 1 ClinicalTrials.gov (NCT01793883) Efficacy and Safety Study of Laninamivir Octanoate TwinCaps? Dry Powder Inhaler in Adults With Influenza
Reference 2 In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection. Arch Med Res. 2015 Jan;46(1):8-16.
Reference 3 Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011 Feb 28;301(2):221-8.
 Download Picture         KEGG Link